Cytomegalovirus antiviral drug resistance: future prospects for prevention, detection and management.
作者信息
Hanson Kimberly E, Swaminathan Sankar
机构信息
Department of Medicine, Division of Infectious Diseases, University of Utah, UT, USA.
Department of Pathology, ARUP Laboratories, University of Utah, UT, USA.
出版信息
Future Microbiol. 2015;10(10):1545-8. doi: 10.2217/fmb.15.82. Epub 2015 Oct 6.
Abstract
摘要
相似文献
1
Cytomegalovirus antiviral drug resistance: future prospects for prevention, detection and management.巨细胞病毒抗病毒药物耐药性：预防、检测与管理的未来前景
Future Microbiol. 2015;10(10):1545-8. doi: 10.2217/fmb.15.82. Epub 2015 Oct 6.
2
Management of cytomegalovirus infection in solid organ transplantation.实体器官移植中巨细胞病毒感染的管理。
Nat Rev Nephrol. 2010 Dec;6(12):711-21. doi: 10.1038/nrneph.2010.141. Epub 2010 Oct 26.
3
Success and failure of artesunate treatment in five transplant recipients with disease caused by drug-resistant cytomegalovirus.青蒿琥酯治疗 5 例耐药物巨细胞病毒病移植受者的疗效和失败。
Antiviral Res. 2014 Jan;101:57-61. doi: 10.1016/j.antiviral.2013.10.014. Epub 2013 Nov 1.
4
Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients.口服马立巴韦治疗移植受者难治性或耐药性巨细胞病毒感染
Transpl Infect Dis. 2010 Dec;12(6):489-96. doi: 10.1111/j.1399-3062.2010.00550.x.
5
Cytomegalovirus drug resistance and clinical implications.巨细胞病毒耐药性及其临床意义。
Transpl Infect Dis. 2001;3 Suppl 2:20-4. doi: 10.1034/j.1399-3062.2001.00004.x.
6
Drug-resistant cytomegalovirus in transplant recipients: a French cohort study.移植受者的耐药巨细胞病毒：法国队列研究。
J Antimicrob Chemother. 2010 Dec;65(12):2628-40. doi: 10.1093/jac/dkq368. Epub 2010 Oct 20.
7
Fast breakthrough of resistant cytomegalovirus during secondary letermovir prophylaxis in a hematopoietic stem cell transplant recipient.造血干细胞移植受者在二次莱曲莫韦预防治疗期间出现耐药巨细胞病毒的快速突破。
BMC Infect Dis. 2019 May 8;19(1):388. doi: 10.1186/s12879-019-4016-1.
8
Refractory/Resistant Cytomegalovirus Infection in Transplant Recipients: An Update.移植受者难治性/耐药巨细胞病毒感染：更新。
Viruses. 2024 Jul 5;16(7):1085. doi: 10.3390/v16071085.
9
New developments in the management of cytomegalovirus infection after solid organ transplantation.实体器官移植后巨细胞病毒感染管理的新进展。
Drugs. 2010 May 28;70(8):965-81. doi: 10.2165/10898540-000000000-00000.
10
Cytomegalovirus pre-emptive therapy after hematopoietic stem cell transplantation in the era of real-time quantitative PCR: comparison with recipients of solid organ transplants.实时定量聚合酶链反应时代造血干细胞移植后巨细胞病毒抢先治疗：与实体器官移植受者的比较
Transpl Infect Dis. 2016 Jun;18(3):405-14. doi: 10.1111/tid.12542. Epub 2016 Jun 9.
引用本文的文献
1
Curcumin derivative C210 induces Epstein-Barr virus lytic cycle and inhibits virion production by disrupting Hsp90 function.姜黄素衍生物 C210 通过破坏 HSP90 功能诱导 Epstein-Barr 病毒裂解周期并抑制病毒粒子的产生。
Sci Rep. 2024 Nov 4;14(1):26694. doi: 10.1038/s41598-024-77294-w.
2
Influence of sphingosine-1-phosphate signaling on HCMV replication in human embryonal lung fibroblasts.鞘氨醇-1-磷酸信号对人胚肺成纤维细胞中 HCMV 复制的影响。
Med Microbiol Immunol. 2018 Aug;207(3-4):227-242. doi: 10.1007/s00430-018-0543-4. Epub 2018 Apr 26.
3
Spironolactone blocks Epstein-Barr virus production by inhibiting EBV SM protein function.螺内酯通过抑制EBV SM蛋白功能来阻断爱泼斯坦-巴尔病毒的产生。
Proc Natl Acad Sci U S A. 2016 Mar 29;113(13):3609-14. doi: 10.1073/pnas.1523686113. Epub 2016 Mar 14.
本文引用的文献
1
Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT.广谱T细胞活性作为异基因造血干细胞移植后腺病毒、EB病毒、巨细胞病毒、BK病毒和人疱疹病毒6型感染的治疗方法。
Sci Transl Med. 2014 Jun 25;6(242):242ra83. doi: 10.1126/scitranslmed.3008825.
2
Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation.更昔洛韦预防造血细胞移植后巨细胞病毒感染。
N Engl J Med. 2014 May 8;370(19):1781-9. doi: 10.1056/NEJMoa1309533.
3
The impact of the prevention strategies on the indirect effects of CMV infection in solid organ transplant recipients.预防策略对实体器官移植受者 CMV 感染间接影响的作用。
Transplant Rev (Orlando). 2014 Apr;28(2):84-91. doi: 10.1016/j.trre.2014.01.001. Epub 2014 Jan 27.
4
Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure.体外筛选使用乐韦替尼（AIC246）后选择的人巨细胞病毒突变体的基因和表型特征。
Antimicrob Agents Chemother. 2014;58(1):610-3. doi: 10.1128/AAC.01794-13. Epub 2013 Nov 4.
5
CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation.CMX001 预防造血细胞移植中的巨细胞病毒病。
N Engl J Med. 2013 Sep 26;369(13):1227-36. doi: 10.1056/NEJMoa1303688.
6
Detection of cytomegalovirus drug resistance mutations by next-generation sequencing.采用下一代测序技术检测巨细胞病毒耐药突变。
J Clin Microbiol. 2013 Nov;51(11):3700-10. doi: 10.1128/JCM.01605-13. Epub 2013 Aug 28.
7
High rate of cytomegalovirus drug resistance among patients receiving preemptive antiviral treatment after haploidentical stem cell transplantation.在接受单倍体造血干细胞移植后进行抢先抗病毒治疗的患者中，巨细胞病毒耐药率较高。
J Infect Dis. 2014 Feb 15;209(4):557-61. doi: 10.1093/infdis/jit475. Epub 2013 Aug 27.
8
Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation.更新的实体器官移植中巨细胞病毒管理的国际共识指南。
Transplantation. 2013 Aug 27;96(4):333-60. doi: 10.1097/TP.0b013e31829df29d.
9
Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance.巨细胞病毒 UL97 激酶催化结构域突变导致多药耐药。
Antimicrob Agents Chemother. 2013 Jul;57(7):3375-9. doi: 10.1128/AAC.00511-13. Epub 2013 May 6.
10
Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation.多中心研究使用第三方储存的病毒特异性 T 细胞治疗造血干细胞移植后严重病毒感染。
Blood. 2013 Jun 27;121(26):5113-23. doi: 10.1182/blood-2013-02-486324. Epub 2013 Apr 22.
Zotero 插件